Timothy J. Scannell net worth and biography

Timothy Scannell Biography and Net Worth

Director of NovoCure

Timothy J. Scannell was elected to our Board in February 2021. He recently retired after a 32-year career at Stryker where he last served as President and Chief Operating Officer from 2018 to 2021. Prior to this position, he served as Group President, responsible for the MedSurg and Neurotechnology businesses at Stryker from 2008-2018. Prior to the Group President role, Mr. Scannell served as President of Stryker Spine and Vice President & General Manager of Stryker Biotech. Mr. Scannell is a Director of Insulet Corporation.

What is Timothy J. Scannell's net worth?: The estimated net worth of Timothy J. Scannell is at least $230.75 thousand as of June 2nd, 2026. Mr. Scannell owns 14,288 shares of NovoCure stock worth more than $230,751 as of June 4th. This net worth estimate does not reflect any other assets that Mr. Scannell may own. Learn More about Timothy J. Scannell's net worth.
How do I contact Timothy J. Scannell?: The corporate mailing address for Mr. Scannell and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at [email protected]. Learn More on Timothy J. Scannell's contact information.
Has Timothy J. Scannell been buying or selling shares of NovoCure?: During the past quarter, Timothy J. Scannell has sold $46,442.65 in shares of NovoCure stock. Most recently, Timothy J. Scannell sold 2,945 shares of the business's stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a transaction totalling $46,442.65. Following the completion of the sale, the director now directly owns 14,288 shares of the company's stock, valued at $225,321.76. Learn More on Timothy J. Scannell's trading history.
Who are NovoCure's active insiders?: NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Christoph Brackmann (CFO), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Executive Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Allyson Ocean (Director), Mukund Paravasthu (COO), Michael Puri (Insider), Timothy Scannell (Director), Pritesh Shah (Insider), Kristin Stafford (Director), William Vernon (Director), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.
Are insiders buying or selling shares of NovoCure?: During the last twelve months, NovoCure insiders bought shares 2 times. They purchased a total of 101,550 shares worth more than $1,228,341.00. During the last twelve months, insiders at the medical equipment provider sold shares 13 times. They sold a total of 157,711 shares worth more than $2,138,772.06. The most recent insider tranaction occured on June, 2nd when Director Gabriel Leung sold 2,945 shares worth more than $46,442.65. Insiders at NovoCure own 5.5% of the company. Learn More about insider trades at NovoCure.
Information on this page was last updated on 6/2/2026.

Timothy J. Scannell Insider Trading History at NovoCure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/2/2026	Sell	2,945	$15.77	$46,442.65	14,288

Timothy J. Scannell Buying and Selling Activity at NovoCure

NovoCure Company Overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Today's Range

Now: $17.99

$16.23

$18.39

50 Day Range

MA: $14.16

$10.35

$18.31

2 Week Range

Now: $17.99

$9.82

$19.25

Volume

744,855 shs

Average Volume

1,764,437 shs

Market Capitalization

$2.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93